Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Eton Pharmaceuticals (ETON) EBITDA Margin (2019 - 2025)

Eton Pharmaceuticals (ETON) has disclosed EBITDA Margin for 7 consecutive years, with 11.05% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin fell 978.0% to 11.05% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1.48% through Dec 2025, up 57.0% year-over-year, with the annual reading at 1.2% for FY2025, 85.0% up from the prior year.
  • EBITDA Margin hit 11.05% in Q4 2025 for Eton Pharmaceuticals, up from 6.07% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 87.41% in Q4 2022 to a low of 754.45% in Q3 2021.
  • Historically, EBITDA Margin has averaged 55.12% across 5 years, with a median of 7.8% in 2023.
  • Biggest YoY gain for EBITDA Margin was 2261419bps in 2021; the steepest drop was -24731177bps in 2021.
  • Year by year, EBITDA Margin stood at 21.57% in 2021, then surged by 305bps to 87.41% in 2022, then crashed by -108bps to 6.69% in 2023, then surged by 411bps to 20.83% in 2024, then plummeted by -47bps to 11.05% in 2025.
  • Business Quant data shows EBITDA Margin for ETON at 11.05% in Q4 2025, 6.07% in Q3 2025, and 7.79% in Q2 2025.